Weighing Benefits and Risks

1993;22(6):1189-1192. 25. Sørensen GV, Cronin-Fenton DP, Sørensen HT, Ulrichsen SP, Pedersen L, Lash TL. Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. Breast Cancer Res. 2012;14(1):R21. doi:10.1186/bcr3106. 26. Schmidt M, Horvath-Puho E, Thomsen RW, Smeeth L, Sørensen HT. Acute infections and venous thromboembolism. J Intern Med. 2012;271(6):608618. 27. Zöller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2012;379(9812):244-249. 28. Tomasson G, Monach PA, Merkel PA. Thromboembolic disease in vasculitis. Curr Opin Rheumatol. 2009;21(1):41-46. 29. Schmidt M, Christiansen CF, Horváth-Puhó E, Glynn RJ, Rothman KJ, Sørensen HT. Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism. J Thromb Haemost. 2011;9(7):1326-1333. 30. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303. 31. Greenland S. Estimation of exposure-specific rates from sparse case-control data. J Chronic Dis. 1987;40(12):1087-1094. 32. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344(8935):1453-1457. 33. Garcı́a Rodrı́guez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45 (5):419-425. 34. Manzoli L, De Vito C, Marzuillo C, Boccia A, Villari P. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf. 2012; 35(3):191-205. 35. Brotman DJ, Girod JP, Posch A, et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res. 2006;118(2):247-252. 36. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med. 1995;332(13):868875. 37. Benchimol EI, Seow CH, Otley AR, Steinhart AH. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):CD002913. doi:10.1002/14651858.CD002913.pub2. 38. Baid SK, Nieman LK. Therapeutic doses of glucocorticoids: implications for oral medicine. Oral Dis. 2006;12(5):436-442. 39. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361(9372):1881-1893. 40. Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991;72(1):39-45. 41. Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf ). 1997;46(3):263-268. 42. Peacey SR, Guo CY, Robinson AM, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf ). 1997;46 (3):255-261. 43. van Langevelde K, Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Cannegieter SC. Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as two sides of the spectrum. Blood. 2012;120(5):933946. 44. Mosbech J, Jørgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen TD. The National Patient Registry: evaluation of data quality [in Danish]. Ugeskr Laeger. 1995;157(26):3741-3745. 45. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83. doi:10.1186/1471-2288-11-83.